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The PI3K signaling axis is frequently activated in cancer resulting from inactivation of its negative regulator
PTEN or activating mutations of the p110a catalytic subunit of PI3K. In this issue of Cancer Cell, Jaiswal et al.
report that mutations in the p85a regulatory subunit of PI3K can also activate this pathway in cancer.Phosphoinositide 3-kinase (PI3K) sig-
naling is often constitutively switched on
in cancer, providing tumor cells with
enhanced capacities for growth, prolifera-
tion, survival, and migration. PI3Ks gen-
erate lipid second messengers inside the
cell to channel signals from upstream
activators at the plasma membrane, such
as receptor tyrosine kinases and Ras, to
downstream effectors, such as the Akt
protein kinase and its many targets. Clin-
ical trials in cancer with small-molecule
inhibitorsagainstPI3Karenow inprogress.
In 2004, DNA sequencing of the kinase
domains of the eight PI3Ks and eight
PI3K-related genes in a large set of mainly
colon cancer samples revealed the pres-
ence of frequent somatic (i.e., cancer cell-
specific) mutations only in the PIK3CA
gene, which encodes the p110a catalytic
subunit of the class I PI3Ks (Samuels
et al., 2004) (Figure 1). Follow-up studies
have confirmed the presence of these
PIK3CA mutations in many types of solid
tumors.
With the exception of the Ras-binding
domain, PIK3CA mutations in cancer are
found throughout the p110a molecule,
clustering in so-called ‘‘hot-spot’’ regions
in the kinase domain and the adjacent
helical domain (Figure 1). The molecular
mechanisms by which these mutations
activate p110a are just beginning to be
unraveled. One mechanism is a possible
facilitation of the binding of p110a to
membranes in the case of the H1047R
mutation (Mandelker et al., 2009). Another
mechanism is through modulation of an
inhibitory interaction of p110awith its regu-
latory subunit encoded by the PIK3R1
gene, as detailed below.
A subset of the p110 catalytic subunits
of PI3Ks, namely p110a, p110b, and
p110d (encoded by PIK3CA, PIK3CB,
and PIK3CD, respectively), constitutively
bind to an SH2 domain-containing proteincalled p85. There are three genes encod-
ing for five p85 species: PIK3R1 encodes
p85a, p55a,s and p50a; PIK3R2 encodes
p85b; and PIK3R3 encodes p55g (Fig-
ure 1). p85s stabilize the intrinsically un-
stable p110 proteins, but also keep them
in a low activity state. Through their SH2
domains, the p85s bind phosphotyrosines
that are generated in receptors and in
receptor-associatedproteinsuponcellular
activation. This recruitment relieves the
p85-mediated inhibitionofp110andbrings
the catalytic subunits in contact with their
lipid substrates at the membranes.
One well-defined mechanism of activa-
tion of p110a by mutation in cancer is that
of theE545Khotspotmutation in thehelical
domain of p110a (Figure 1). This mutation
relieves the basal repression of p85a on
p110a through disruption of an inhibitory
charge-charge interaction between the
two proteins. Thus, p85a no longer inhibits
p110a-E545K. Interestingly, through artifi-
cial introduction of specific mutations in
p85a, it was possible to restore the inhibi-
tion of p85a on p110a-E545K (Miled et al.,
2007). This suggested that naturally occur-
ring PIK3R1 mutations should in principle
also be capable of activating wild-type
p110a.
Over the years, there have been several
reports of low-frequency mutations or
deletions in PIK3R1 in cancer, and this
has now been confirmed by recent high
throughput DNA sequencing efforts
(Parsons et al., 2008; TCGA, 2008; Wood
et al., 2007) and by Jaiswal et al. (2009),
in this issue of Cancer Cell. Interestingly,
many (but not all) of these mutations
cluster in the two SH2 domains and the
so-called inter-SH2 domain they flank,
through which p85 binds p110 (Figure 1).
Jaiswail et al. characterized a number of
these p85a mutants in detail, including
D560Y, N564D, and QYL579 delL. The
latter encodes a p85a mutant that hasCancer Cell 16,a two amino acids deletion in the iSH2
domain but maintains p110-binding
activity. They found that these mutants
retain their ability to stabilize p110a but
lose their inhibitory activity. Further bio-
logical studies revealed an enhanced
capacity of these p85a mutants to
increase Akt signaling, cell survival,
anchorage-independent cell growth, and
tumorigenesis in nude mice.
A remarkable pattern of selectivity of
PI3K mutation in cancer is starting to
emerge. Compared to p110a and p85a/
p55a/p50a, the frequency of mutation
in other catalytic-regulatory subunits is
extremely low or absent (Jaiswal et al.,
2009 and Figure 1). This is somewhat
surprising, given that p110b and p85b
are also highly expressed in tissues and
cancer cells (Geering et al., 2007). More-
over, upon artificial coexpression in cells,
each p110 isoform can bind any p85
species, but it is not clear whether endog-
enous p110 isoforms have a preference
for specific p85 isoforms. Taken together,
these data indicate that p110a, possibly
when in complex with p85a, has cancer-
relevant functional characteristics that
are not shared by other PI3K complexes.
Interestingly, Jaswail et al. show that
PIK3R1 mutations can also activate
p110b and p110d. Thus, even when not
mutated in cancer, p110b and p110d
can be activated by mutation of p85a,
clearly broadening the mechanisms by
which the PI3K pathway can be activated
in cancer. p110b and p110d can be over-
expressed in human cancer and can
induce characteristics of transformation
in chicken embryo fibroblasts (Kang
et al., 2006). If co-occurring in the context
of enhanced p110b or p110d expression,
mutated p85a could even further enhance
the activities of these nonmutated cata-
lytic subunits. Of interest from a thera-
peutic perspective, all mutant p85a/p110December 8, 2009 ª2009 Elsevier Inc. 449
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Figure 1. Cancer Mutations in PI3K Family Members
The left panel shows the frequency of mutation in cancer in the different PI3K family members. The right
panel shows the location of mutations (indicated by arrowheads) in p110a and p85a. The mutations that
are discussed in the text are spelled out. Not shown are the p55a and p50a proteins, which are encoded by
transcripts from the PIK3R1 gene through alternative promoter usage. Compared to p85a, p55a and p50a
contain the same SH2 domains and the iSH2 domain but a smaller N-terminal extension.complexes tested were found to retain
their sensitivity to PI3K inhibitors that
were generated against the wild-type
p110 proteins. In other words, mutation
of p85a would not necessarily lead to
therapeutic resistance.
An important question raised by the
work of Jaiswal et al. is whether these
‘‘oncogenic’’ mutations in p85a are driver
mutations in cancer or secondary muta-
tions that help tumor development once
cells have acquired a tumor-prone genetic
profile by other means. How they are
implicated in cancer may also depend on
the tissue and cell type, as suggested by
the pattern of co-occurrence with other
oncogenic alterations in the PI3K path-
way. For example, in colon cancer, most
PIK3CA mutations do not co-occur with
PIK3R1 mutations. However, when a
PIK3R1 mutation is found, half of these
also have a PIK3CA mutation. Moreover,
22% of the samples with a PIK3R1 muta-450 Cancer Cell 16, December 8, 2009 ª200tion also have a PTEN mutation (Jaiswal
et al., 2009). To the contrary, in glioblas-
toma, PIK3R1 mutations do not co-occur
with PIK3CA mutations (Parsons et al.,
2008; TCGA, 2008) and very rarely with
PTEN mutations, despite the high
frequency of the latter in this tumor type.
However, these data need to be inter-
preted carefully because finding two
mutations in the same tissue sample
does not necessarily mean that they
have occurred in the same cancer cell.
Can the presence of p85amutations be
used as a diagnostic marker to identify
cancers that are dependent on PI3K,
and thus identify good candidates for
treatment with PI3K pathway inhibitors?
Ongoing studies suggest that there is no
good correlation between the presence
of p110a mutations and sensitivity to
PI3K inhibitors, at least in cultured cancer
cell lines. The same applies for inactiva-
tion of PTEN. It is therefore not entirely9 Elsevier Inc.clear what the predictive value of the p85a
mutations will be, in terms of inhibitor
sensitivity, and it is quite likely that other
lesions may have a modulating effect on
pathway sensitivity. The real challenge
will be to build a comprehensive genetic
landscape surrounding PI3K alterations
in different cancers in order to better
predict sensitivity to inhibitors targeting
this pathway. Such efforts are in progress
(Sos et al., 2009).
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